Every 10-Q that Profusa, Inc. (PFSA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PFSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PFSA filings page.
Profusa, Inc. (PFSA) reports very strained finances for the quarter ended June 30, 2026. Cash was only $0.7 million with total assets of $1.0 million against total liabilities of $28.2 million, resulting in a stockholders’ deficit of $27.1 million. The company discloses a working capital deficit of about $27.3 million and states that there is substantial doubt about its ability to continue as a going concern within one year.
Profusa recorded a six‑month net loss of $12.2 million and used $5.2 million of cash in operating activities, driven by higher R&D and G&A and large non‑cash financing costs and fair‑value losses on convertible notes. Liquidity currently depends on external financing: the company has a $100 million Equity Line of Credit with Ascent, of which $86.9 million remained available, and remaining borrowing capacity under its Ascent PIPE facility, though future draws are subject to investor discretion and conditions. Profusa also outlines significant Nasdaq listing risk; it has executed multiple reverse stock splits and believes it now meets a $2.5 million stockholders’ equity standard but is awaiting formal Nasdaq confirmation, and warns that failure to comply could lead to delisting and further restrict capital access.
Profusa, Inc. reported a net loss of $3.5 million for the three months ended March 31 2026, compared with $2.7 million a year earlier, as research and development and legal and accounting costs increased. Cash fell to $0.4 million from $1.8 million at year‑end, while total liabilities were $29.1 million against total assets of $0.9 million, leaving a stockholders’ deficit of $28.2 million. The company recorded a $1.4 million gain from forgiveness of its remaining PPP loan but also realized a $0.3 million loss exiting its Bitcoin treasury strategy. Management disclosed a working capital deficit of about $28.4 million and concluded that substantial doubt exists about its ability to continue as a going concern, relying on an equity line of credit, PIPE notes and future financings to fund operations while pursuing regulatory approvals and commercialization of its Lumee Oxygen and Lumee Glucose platforms and navigating Nasdaq listing compliance.
Profusa, Inc. (PFSA) reports sharply higher losses and liquidity strain for the nine months ended September 30, 2025. Net loss widened to $27.3 million from $7.0 million a year earlier as operating expenses, mainly general and administrative, rose to $24.1 million. Cash was $3.0 million with a working capital deficit of about $19.3 million, and management states there is substantial doubt about the company’s ability to continue as a going concern.
The company closed its business combination with NorthView Acquisition Corporation, converting preferred stock and much of its convertible debt into common stock, and raised funding through a PIPE structure and an equity line of credit. Profusa issued a $10.0 million PIPE convertible note and, under a committed equity facility of up to $100.0 million, sold roughly $3.5 million of common shares by September 30. It also bought 8.53 Bitcoin for about $1.0 million as part of a treasury strategy.
Nazdaq notified Profusa that its market value of listed securities has fallen below $50.0 million and its share price below $1.00, triggering two 180‑day compliance periods ending on March 10, 2026. Failure to regain compliance could lead to delisting, adding to the company’s financing and execution risks as it works toward commercializing its Lumee Oxygen and Glucose platforms.
Profusa, Inc. (PFSA) 10-Q highlights key balance sheet and financing events tied to its SPAC combination and trust account activity. The company reports a working capital deficit of $15,492,554 and restricted cash of $1,751. It continues to hold funds in a Trust Account funded initially with IPO proceeds (approximately $191,647,500 placed in the Trust Account), and sold 18,975,000 Units in its IPO generating gross proceeds of $189,750,000. The company presents significant liabilities recorded at fair value including warrant liabilities (public and private) and a related-party convertible promissory note presented at fair value of $10,288,111 as of June 30, 2025. Management discloses substantial doubt about the company’s ability to continue as a going concern within one year of issuance of the condensed consolidated financial statements. The filing also records an excise tax liability related to share redemptions of $1,952,662.